Adoptive cell transfer (ACT) of purified naive, stem cell memory, and central memory T cell subsets results in superior persistence and antitumor immunity compared with ACT of populations containing more-differentiated effector memory and effector T cells. Despite a clear advantage of the less-differentiated populations, the majority of ACT trials utilize unfractionated T cell subsets. Here, we have challenged the notion that the mere presence of less-differentiated T cells in starting populations used to generate therapeutic T cells is sufficient to convey their desirable attributes. Using both mouse and human cells, we identified a T cell–T cell interaction whereby antigen-experienced subsets directly promote the phenotypic, functional, and metabolic differentiation of naive T cells. This process led to the loss of less-differentiated T cell subsets and resulted in impaired cellular persistence and tumor regression in mouse models following ACT. The T memory–induced conversion of naive T cells was mediated by a nonapoptotic Fas signal, resulting in Akt-driven cellular differentiation. Thus, induction of Fas signaling enhanced T cell differentiation and impaired antitumor immunity, while Fas signaling blockade preserved the antitumor efficacy of naive cells within mixed populations. These findings reveal that T cell subsets can synchronize their differentiation state in a process similar to quorum sensing in unicellular organisms and suggest that disruption of this quorum-like behavior among T cells has potential to enhance T cell–based immunotherapies.
Christopher A. Klebanoff, Christopher D. Scott, Anthony J. Leonardi, Tori N. Yamamoto, Anthony C. Cruz, Claudia Ouyang, Madhu Ramaswamy, Rahul Roychoudhuri, Yun Ji, Robert L. Eil, Madhusudhanan Sukumar, Joseph G. Crompton, Douglas C. Palmer, Zachary A. Borman, David Clever, Stacy K. Thomas, Shashankkumar Patel, Zhiya Yu, Pawel Muranski, Hui Liu, Ena Wang, Francesco M. Marincola, Alena Gros, Luca Gattinoni, Steven A. Rosenberg, Richard M. Siegel, Nicholas P. Restifo
Title and authors | Publication | Year |
---|---|---|
Defining a TCF1-expressing progenitor allogeneic CD8 T cell subset in acute graft-versus-host disease
Solhwi Lee, Kunhee Lee, Hyeonjin Bae, Kyungmin Lee, Junghwa Lee, Junhui Ma, Ye Lee, Bo Lee, Woong-Yang Park, Se Im |
Nature Communications | 2023 |
Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy
Sharma S, Woods M, Mehta NU, Sauer T, Parikh KS, Schmuck-Henneresse M, Zhang H, Mehta B, Brenner MK, Heslop HE, Rooney CM |
Journal for ImmunoTherapy of Cancer | 2023 |
IL-15 promotes self-renewal of progenitor exhausted CD8 T cells during persistent antigenic stimulation
Lee J, Lee K, Bae H, Lee K, Lee S, Ma J, Jo K, Kim I, Jee B, Kang M, Im SJ |
Frontiers in immunology | 2023 |
Glucose oxidation-dependent survival of activated B cells provides a putative novel therapeutic target for lupus treatment
Wilson JJ, Wei J, Daamen AR, Sears JD, Bechtel E, Mayberry CL, Stafford GA, Bechtold L, Grammer AC, Lipsky PE, Roopenian DC, Chang CH |
iScience | 2023 |
CD62L as target receptor for specific gene delivery into less differentiated human T lymphocytes
Kapitza L, Ho N, Kerzel T, Frank AM, Thalheimer FB, Jamali A, Schaser T, Buchholz CJ, Hartmann J |
Frontiers in immunology | 2023 |
AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
Sakemura RL, Hefazi M, Cox MJ, Siegler EL, Sinha S, Hansen MJ, Stewart CM, Feigin JM, Roman CM, Schick KJ, Can I, Tapper EE, Horvei P, Adada MM, Bezerra ED, Fonkoua LA, Ruff MW, Forsman CL, Nevala WK, Boysen JC, Tschumper RC, Grand CL, Kuchimanchi KR, Mouritsen L, Foulks JM, Warner SL, Call TG, Parikh SA, Ding W, Kay NE, Kenderian SS |
Cancer immunology research | 2023 |
The alterations in peripheral lymphocyte subsets predict the efficacy and prognosis of immune checkpoint inhibitors in hepatocellular carcinoma
Xie Q, Hu C, Luo C |
Journal of Cancer | 2023 |
Cell Granularity Reflects Immune Cell Function and Enables Selection of Lymphocytes with Superior Attributes for Immunotherapy
Wu T, Tan JH, Sin W, Luah YH, Tan SY, Goh M, Birnbaum ME, Chen Q, Cheow LF |
Advanced Science | 2023 |
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies.
Ruella M, Korell F, Porazzi P, Maus MV |
Nature reviews. Drug discovery | 2023 |
DIALing-up the preclinical characterization of gene-modified adoptive cellular immunotherapies
Giardino Torchia ML, Moody G |
Frontiers in immunology | 2023 |
Molecular and temporal control of restimulation-induced cell death (RICD) in T lymphocytes
Lee KP, Epstein B, Lake CM, Snow AL |
2023 |